chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: M
Vaccine: COVID19
Symptoms: Bronchitis, Illness
Clinical narrative: VERY SICK; BRONCHITIS; This spontaneous report received from a patient concerned a 70 year old male of an unspecified race and ethnic origin. The patient's height, and weight were not reported. The patient's concurrent conditions included: covid-19, and pneumonia (The patient said he received negligent care from well known entity, horrible care years ago and that is why his health was compromised from the pneumonia.), and other pre-existing medical conditions included: The patient reported that he was an athlete for a long time and enjoyed superior health and can still knock out at least 20 push ups on demand. He said he has a job that gives him unusual exposure to cold drafty air things that would be highly susceptible for people to get a cold. His line of work exposes him to that. He reported that his health was not what it used to be. The patient previously received covid-19 vaccine ad26.cov2.s (dose number in series 1) suspension for injection, route of admin, and batch number were not reported) 1 in total, dose, start therapy date were not reported for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26.cov2.s (dose number in series 1). The patient additionally received covid-19 vaccine ad26.cov2.s (dose number in series 2) (suspension for injection, route of admin, and batch number were not reported) 1 in total, dose, start therapy date were not reported for covid-19 prophylaxis. The batch number was not reported and has been requested. No concomitant medications were reported.  On an unspecified date, the patient experienced very sick, and bronchitis with cold draft air hours upon hours (dose number in series 2). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the very sick and bronchitis was not reported. This report was non-serious.
Sex: U
Vaccine: COVID19
Symptoms: Acute febrile neutrophilic dermatosis
Clinical narrative: SWEET SYNDROME; This spontaneous report received from a consumer via a company representative concerned a patient of unspecified age, race, ethnicity and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, batch number and expiry date were not reported) dose, start therapy date were not reported, 1 total administered for covid-19 prophylaxis. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On an unspecified date, the patient experienced atypical presentation of Sweet syndrome with nodular erythema and oral ulcerations. The patient was vaccinated 7 days prior to the first symptoms experienced by the patient. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of sweet syndrome was not reported. This report was serious (Other Medically Important Condition). This report was associated with a product quality complaint: 90000280091.; Sender's Comments: V0: 20230449728-Sweet syndrome. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event. Therefore, the WHO Causality is considered indeterminate. The company causality is considered unassessable.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Memory impairment
Clinical narrative: CANNOT REMEMBER THING LATELY/WORRIED ABOUT FORGETTING ADDRESS/HEAD NOT DOING WELL/PROBLEMS WITH MEMORY/IT HAD BEEN BOTHERING FOR A LONG TIME AND SHE HAD NOT BEEN THE SAME; This spontaneous report received from a patient concerned an 84 year old female. The patient's weight was 140 pounds, and height was 64 inches. The patient's concurrent conditions included: blood pressure, sugar, sulfa allergy, non-alcohol user, and non-smoker, and other pre-existing medical conditions included: The patient had no history of drug abuse or illicit drug usage. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on APR-2022 for covid-19 prophylaxis. The batch number was not reported and has been requested. Age at time of vaccination 84 years old. Concomitant medications included acetylsalicylic acid, and metformin. On 2022, the patient experienced cannot remember thing lately/worried about forgetting address/head not doing well/problems with memory/it had been bothering for a long time and she had not been the same. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from cannot remember thing lately/worried about forgetting address/head not doing well/problems with memory/it had been bothering for a long time and she had not been the same. This report was non-serious.
Sex: U
Vaccine: COVID19-2
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; Patients received a dosage of 0.2 ml of the bivalent vaccine dark pink cap with yellow border as their primary dose; This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patients received a dosage of 0.2 ml of the bivalent vaccine dark pink cap with yellow border as their primary dose) and NO ADVERSE EVENT (No adverse event) in an infant patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 216K22A) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: Rotavirus (Rota tec), Pediarix, ACT Hib and PCV 13. Past adverse reactions to the above products included No adverse event with ACT Hib, PCV 13, Pediarix and Rotavirus (Rota tec). Concurrent medical conditions included Lactose intolerant and Cow's milk protein allergy.    On 19-Apr-2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .2 milliliter. On 19-Apr-2023, the patient experienced WRONG PRODUCT ADMINISTERED (Patients received a dosage of 0.2 ml of the bivalent vaccine dark pink cap with yellow border as their primary dose). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Patients received a dosage of 0.2 ml of the bivalent vaccine dark pink cap with yellow border as their primary dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Patients received a dosage of 0.2 ml of the bivalent vaccine dark pink cap with yellow border as their primary dose).    It was reported that patient received other vaccines in the 4 weeks prior to COVID-19 vaccine. No concomitant medications was reported. No treatment drug details was reported.  This case contains information for the 3rd patient out of 4 infant patients as described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-720512 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-720512:Infant Patient - 1 (master case)
Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: The vial was initially stored in the refrigerator on 16-Mar-2023; no adverse event; Dose administered after 30-day Use By Date or after manufacturer date of expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date or after manufacturer date of expiry), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 16-Mar-2023) and NO ADVERSE EVENT (no adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 066H22A) for COVID-19 prophylaxis.     No Medical History information was reported.  On 20-Apr-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .5 milliliter. On 20-Apr-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date or after manufacturer date of expiry). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 16-Mar-2023) and NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date or after manufacturer date of expiry), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 16-Mar-2023) and NO ADVERSE EVENT (no adverse event) outcome was unknown.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date or after manufacturer date of expiry) and PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 16-Mar-2023).    No concomitant medications were reported.  It was unknown if the patient receive any other vaccines in the 4 weeks prior to COVID-19 vaccine. The BUD was reported as 15-Apr-2023.  The vial was initially stored in the refrigerator on 16-Mar-2023. The vial did not undergo any temperature excursions.  No treatment medications were reported.  This case contains information for the 3 of 5th adult patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-720516 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-720516:1st patient case (Master case)
Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: The vial was initially stored in the refrigerator on 16-Mar-2023 and dose was administered on 20-Apr-2023; No adverse event; 5 boosters were administered on 20-Apr-2023 that had BUD 15-Apr-2023; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (5 boosters were administered on 20-Apr-2023 that had BUD 15-Apr-2023), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 16-Mar-2023 and dose was administered on 20-Apr-2023) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 066H22A) for COVID-19 prophylaxis.     It was unknown if the patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.     On 20-Apr-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .5 milliliter. On 20-Apr-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (5 boosters were administered on 20-Apr-2023 that had BUD 15-Apr-2023). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 16-Mar-2023 and dose was administered on 20-Apr-2023) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (5 boosters were administered on 20-Apr-2023 that had BUD 15-Apr-2023), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 16-Mar-2023 and dose was administered on 20-Apr-2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (5 boosters were administered on 20-Apr-2023 that had BUD 15-Apr-2023) and PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 16-Mar-2023 and dose was administered on 20-Apr-2023).    Concomitant medication was not provided.  Vial size was reported as 2.5 ml. The vial was initially stored in the refrigerator on 16-Mar-2023. Vial did not undergo any temperature excursions. No treatment information was provided This case contains information for the 4th patient out of 5 adult patients as described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-720516 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-720516:1st patient case (Master case)
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: The vial was initially stored in the refrigerator on 06-JUL-2022 and was administered from 19-Sep-2022 until 09-Nov-2022; No adverse event; Adult patient received expired Monovalent booster dose of Moderna COVID-19 vaccine.; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Adult patient received expired Monovalent booster dose of Moderna COVID-19 vaccine.), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 06-JUL-2022 and was administered from 19-Sep-2022 until 09-Nov-2022) and NO ADVERSE EVENT (No adverse event) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 051B22A) for COVID-19 prophylaxis.     No Medical History information was reported.    In 2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Adult patient received expired Monovalent booster dose of Moderna COVID-19 vaccine.). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 06-JUL-2022 and was administered from 19-Sep-2022 until 09-Nov-2022) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Adult patient received expired Monovalent booster dose of Moderna COVID-19 vaccine.), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 06-JUL-2022 and was administered from 19-Sep-2022 until 09-Nov-2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Adult patient received expired Monovalent booster dose of Moderna COVID-19 vaccine.) and PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 06-JUL-2022 and was administered from 19-Sep-2022 until 09-Nov-2022).    No concomitant information was reported. It was reported that monovalent vials of Moderna COVID-19 vaccine in the freezer moved to the refrigerator on 06-JUL-2022 and beyond use date was 05-AUG-2022. The unknown vial did not underwent any temperature excursions. This case is reported for 3rd patient out of 12 patients. No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-720531 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-720531:
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: 12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19SEP2022 until 09NOV2022. 9 Boosters 3rd dose and 3 second doses (Lot# 051B22A & Exp. Date: unknown); Dose administered after 30-day Use By Date:; No adverse event; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19SEP2022 until 09NOV2022. 9 Boosters 3rd dose and 3 second doses (Lot# 051B22A & Exp. Date: unknown)), PRODUCT STORAGE ERROR (Dose administered after 30-day Use By Date:) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 051B22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19SEP2022 until 09NOV2022. 9 Boosters 3rd dose and 3 second doses (Lot# 051B22A & Exp. Date: unknown)), PRODUCT STORAGE ERROR (Dose administered after 30-day Use By Date:) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19SEP2022 until 09NOV2022. 9 Boosters 3rd dose and 3 second doses (Lot# 051B22A & Exp. Date: unknown)), PRODUCT STORAGE ERROR (Dose administered after 30-day Use By Date:) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19SEP2022 until 09NOV2022. 9 Boosters 3rd dose and 3 second doses (Lot# 051B22A & Exp. Date: unknown)) and PRODUCT STORAGE ERROR (Dose administered after 30-day Use By Date:).    No concomitant medications were reported.  Monovalent vials of Moderna COVID-19 vaccine in the freezer moved to the refrigerator on 06-Jul-2022 and Beyond use date was 05-Aug-2022. 12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19-Sep-2022 until 09-Nov-2022. 9 Boosters were 3rd dose and 3 second doses. No previous excursion was there. Beyond use date was 05-AUG-2022.  The vial was initially stored in the refrigerator on 06-Jul-2022. 6 Patients received on 19-Sep-2022, 2 Patients 04-Oct-2022, 1 Patients on 06-Oct-2022, 1 Patient on 09-Nov-2022.   The vial did not undergo any temperature excursions.  No treatment medications were reported.  This case contains information for the 4th of 12th adult patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-720531 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-720531:
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Patient received expired dose of vaccine; The vial was initially stored in the refrigerator on 06-Jul-2022; No adverse event; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received expired dose of vaccine), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 06-Jul-2022 ) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 051B22A) for COVID-19 prophylaxis.     No Medical History information was reported.  On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received expired dose of vaccine), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 06-Jul-2022 ) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient received expired dose of vaccine), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 06-Jul-2022 ) and NO ADVERSE EVENT (No adverse event) outcome was unknown.     For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Patient received expired dose of vaccine) and PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 06-Jul-2022 ).    No concomitant medications were reported.  Monovalent vials of Moderna COVID-19 vaccine in the freezer moved to the refrigerator on 06-Jul-2022 and Beyond use date was 05-Aug-2022. 12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19-Sep-2022 until 09-Nov-2022. 9 Boosters were 3rd dose and 3 second doses. No previous excursion was there.  The vial was initially stored in the refrigerator on 06-Jul-2022. 6 Patients received on 19-Sep-2022, 2 Patients 04-Oct-2022, 1 Patients on 06-Oct-2022, 1 Patient on 09-Nov-2022.   The vial did not undergo any temperature excursions.  No treatment medications were reported.  This case contains information for the 5th of 12th adult patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-720531 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-720531:
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: 12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19SEP2022 until 09NOV2022; Vaccine were stored in refrigerator after beyond use date; No adverse event; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19SEP2022 until 09NOV2022), PRODUCT STORAGE ERROR (Vaccine were stored in refrigerator after beyond use date) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 051B22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19SEP2022 until 09NOV2022), PRODUCT STORAGE ERROR (Vaccine were stored in refrigerator after beyond use date) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19SEP2022 until 09NOV2022), PRODUCT STORAGE ERROR (Vaccine were stored in refrigerator after beyond use date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19SEP2022 until 09NOV2022) and PRODUCT STORAGE ERROR (Vaccine were stored in refrigerator after beyond use date).    Concomitant medication was not provided.   Monovalent vials of Moderna COVID-19 vaccine in the freezer moved to the refrigerator on 06-JUL-2022 and Beyond use date was 05-AUG-2022. 12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19-SEP-2022 until 09-NOV-2022. 9 Boosters 3rd dose and 3 second doses. No previous excursion. The vaccine was administered to 6 Patients on 19-SEP-2022, 2 Patients 04-OCT-2022, 1 Patients 06-OCT-2022, 1 Patient on 09-NOV-2022.  Treatment information was not provided.  This case contains information for the 6th patient out of 12 adult patients as described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-720531 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-720531:
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: 12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19SEP2022 until 09NOV2022; Vaccine were stored in refrigerator after beyond use date; No adverse event; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19SEP2022 until 09NOV2022), PRODUCT STORAGE ERROR (Vaccine were stored in refrigerator after beyond use date) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 051B22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19SEP2022 until 09NOV2022), PRODUCT STORAGE ERROR (Vaccine were stored in refrigerator after beyond use date) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19SEP2022 until 09NOV2022), PRODUCT STORAGE ERROR (Vaccine were stored in refrigerator after beyond use date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19SEP2022 until 09NOV2022) and PRODUCT STORAGE ERROR (Vaccine were stored in refrigerator after beyond use date).    No concomitant medications was reported.  Monovalent vials of Moderna COVID-19 vaccine in the freezer moved to the refrigerator on 06-JUL-2022 and Beyond use date was 05-AUG-2022. 12 Adult patients received Expired Monovalent dose of Moderna COVID-19 vaccine 19-SEP-2022 until 09-NOV-2022. 9 Boosters 3rd dose and 3 second doses. No previous excursion. The vaccine was administered to 6 Patients on 19-SEP-2022, 2 Patients 04-OCT-2022, 1 Patients 06-OCT-2022, 1 Patient on 09-NOV-2022.  No treatment medications was reported.  This case contains information about Patient 9th out of 12 Patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-720531 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-720531:
Sex: F
Vaccine: COVID19-2
Symptoms: Maternal exposure during pregnancy, No adverse event, Wrong product administered
Clinical narrative: She did receive her first shot i will do an AE on her because of the pregnancy; The patient received first dose of bivalent vaccine; No Adverse Event; This spontaneous prospective pregnancy case was reported by a patient and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (She did receive her first shot i will do an AE on her because of the pregnancy), WRONG PRODUCT ADMINISTERED (The patient received first dose of bivalent vaccine) and NO ADVERSE EVENT (No Adverse Event) in an adult female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On an unknown date, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (She did receive her first shot i will do an AE on her because of the pregnancy), WRONG PRODUCT ADMINISTERED (The patient received first dose of bivalent vaccine) and NO ADVERSE EVENT (No Adverse Event). At the time of the report, MATERNAL EXPOSURE DURING PREGNANCY (She did receive her first shot i will do an AE on her because of the pregnancy) had resolved and WRONG PRODUCT ADMINISTERED (The patient received first dose of bivalent vaccine) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.        The action taken with mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown) was unknown.   For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse Event) to be not related. No further causality assessments were provided for MATERNAL EXPOSURE DURING PREGNANCY (She did receive her first shot i will do an AE on her because of the pregnancy) and WRONG PRODUCT ADMINISTERED (The patient received first dose of bivalent vaccine).    Concomitant medications and treatment medications were not reported.  Company comment. This non  serious spontaneous case concerns an adult female patient, with no medical history reported, with maternal exposure during pregnancy and no adverse event reported. It was stated that the patient received a first dose with mRNA  1273.222 (Original/Omicron BA.4/5) vaccine. Additionally, wrong product administered was noted. Gestational period was not disclosed. No further clinical details were provided for medical reviewing. The benefit-risk relationship of mRNA  1273.222 (Original/Omicron BA.4/5) vaccine is not affected by this report.   Reporter did not allow further contact
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product administration interrupted
Clinical narrative: Patient received first dose on 20Jan2023; No adverse event; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT ADMINISTRATION INTERRUPTED (Patient received first dose on 20Jan2023) and NO ADVERSE EVENT (No adverse event) in a 35-year-old female patient who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.    On 20-Jan-2023, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (Patient received first dose on 20Jan2023) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTRATION INTERRUPTED (Patient received first dose on 20Jan2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for PRODUCT ADMINISTRATION INTERRUPTED (Patient received first dose on 20Jan2023).    No concomitant medication details was reported. No treatment medication details was reported.
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product administration interrupted
Clinical narrative: Received first primary series dose but are now outside the 1-month window for a second primary series dose/ Received primary dose on 30J-an-2023, and needs second dose but can't find it.; no adverse event; This spontaneous case was reported by a patient family member or friend and describes the occurrence of PRODUCT ADMINISTRATION INTERRUPTED (Received first primary series dose but are now outside the 1-month window for a second primary series dose/ Received primary dose on 30J-an-2023, and needs second dose but can't find it.) and NO ADVERSE EVENT (no adverse event) in a child male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.    On 30-Jan-2023, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (Received first primary series dose but are now outside the 1-month window for a second primary series dose/ Received primary dose on 30J-an-2023, and needs second dose but can't find it.) and NO ADVERSE EVENT (no adverse event). At the time of the report, PRODUCT ADMINISTRATION INTERRUPTED (Received first primary series dose but are now outside the 1-month window for a second primary series dose/ Received primary dose on 30J-an-2023, and needs second dose but can't find it.) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessment was provided for PRODUCT ADMINISTRATION INTERRUPTED (Received first primary series dose but are now outside the 1-month window for a second primary series dose/ Received primary dose on 30J-an-2023, and needs second dose but can't find it.).    No concomitant medications were reported.  No treatment information was provided.   Reporter did not allow further contact
Age: 68.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Vials were stored in the fridge for more than 30 days; No adverse event; HCP stated they accidentally administered 3 doses of Moderna COVID-19 Vaccine after more than 30 days that vials were stored in the fridge.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 3 doses of Moderna COVID-19 Vaccine after more than 30 days that vials were stored in the fridge.), PRODUCT STORAGE ERROR (Vials were stored in the fridge for more than 30 days) and NO ADVERSE EVENT (No adverse event) in a 68-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7171B) for COVID-19 prophylaxis.     It was unknown if patient had any relevant medical history, allergy,concomitant diseases and risk factor and also unknown if received any other vaccines in the 4 weeks prior to COVID-19 vaccine.     On 17-Apr-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 17-Apr-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 3 doses of Moderna COVID-19 Vaccine after more than 30 days that vials were stored in the fridge.). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vials were stored in the fridge for more than 30 days) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 3 doses of Moderna COVID-19 Vaccine after more than 30 days that vials were stored in the fridge.), PRODUCT STORAGE ERROR (Vials were stored in the fridge for more than 30 days) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 3 doses of Moderna COVID-19 Vaccine after more than 30 days that vials were stored in the fridge.) and PRODUCT STORAGE ERROR (Vials were stored in the fridge for more than 30 days).    No concomitant information was reported. Suspect product dosage text was reported as initial booster. It was unknown if patient number 2 experienced any adverse events. No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-720524, US-MODERNATX, INC.-MOD-2023-720530 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-720524:same reporter US-MODERNATX, INC.-MOD-2023-720530:same reporter
Age: 4.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Wrong product administered
Clinical narrative: no adverse event; I have a 4 year old who was supposed to receive a dose of the bivalent vaccine but received a monovalent vaccine instead; This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (I have a 4 year old who was supposed to receive a dose of the bivalent vaccine but received a monovalent vaccine instead) and NO ADVERSE EVENT (no adverse event) in a 4-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AS1415B) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: PFIZER BIONTECH COVID-19 VACCINE (lot number SL8095, Dose 1) on 29-Jun-2022, PFIZER BIONTECH COVID-19 VACCINE (lot number ST9142 and Dose 2) on 16-Sep-2022. Past adverse reactions to the above products included No adverse event with PFIZER BIONTECH COVID-19 VACCINE and PFIZER BIONTECH COVID-19 VACCINE.    On 20-Apr-2023, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Apr-2023,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced WRONG PRODUCT ADMINISTERED (I have a 4 year old who was supposed to receive a dose of the bivalent vaccine but received a monovalent vaccine instead). On an unknown date, the patient experienced NO ADVERSE EVENT (no adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (I have a 4 year old who was supposed to receive a dose of the bivalent vaccine but received a monovalent vaccine instead) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (I have a 4 year old who was supposed to receive a dose of the bivalent vaccine but received a monovalent vaccine instead).    No concomitant medications was reported. No symptoms was reported. No treatment drug details was reported.
Age: 36.0
Sex: M
Vaccine: COVID19-2
Symptoms: Extra dose administered, No adverse event, Syringe issue, Underdose
Clinical narrative: No adverse event; 2nd Bivalent dose; 2nd Bivalent dose (Partial dose) of Moderna COVID-19 vaccine; syringe leaked at time of administration; This spontaneous case was reported by a pharmacist and describes the occurrence of EXTRA DOSE ADMINISTERED (2nd Bivalent dose), UNDERDOSE (2nd Bivalent dose (Partial dose) of Moderna COVID-19 vaccine), SYRINGE ISSUE (syringe leaked at time of administration) and NO ADVERSE EVENT (No adverse event) in a 36-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 065H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 19-Apr-2023, the patient received seventh dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 19-Apr-2023, the patient experienced EXTRA DOSE ADMINISTERED (2nd Bivalent dose), UNDERDOSE (2nd Bivalent dose (Partial dose) of Moderna COVID-19 vaccine) and SYRINGE ISSUE (syringe leaked at time of administration). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXTRA DOSE ADMINISTERED (2nd Bivalent dose), UNDERDOSE (2nd Bivalent dose (Partial dose) of Moderna COVID-19 vaccine), SYRINGE ISSUE (syringe leaked at time of administration) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXTRA DOSE ADMINISTERED (2nd Bivalent dose), UNDERDOSE (2nd Bivalent dose (Partial dose) of Moderna COVID-19 vaccine) and SYRINGE ISSUE (syringe leaked at time of administration).    No concomitant medications was reported. No treatment medications was reported.
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event, Wrong product administered
Clinical narrative: The vaccine was administered after the indications changed and the monovalent is no longer authorized.; No Adverse Event; HCP stated a patient received 1 dose of Moderna COVID-19 Vaccine monovalent on 20 APR 2023 for the 2nd dose of the primary series, but the vaccine expired on 30 MAR 2023.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (HCP stated a patient received 1 dose of Moderna COVID-19 Vaccine monovalent on 20 APR 2023 for the 2nd dose of the primary series, but the vaccine expired on 30 MAR 2023.), WRONG PRODUCT ADMINISTERED (The vaccine was administered after the indications changed and the monovalent is no longer authorized.) and NO ADVERSE EVENT (No Adverse Event) in an adult patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 042C22A) for COVID-19 prophylaxis.     It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.     On 20-Apr-2023, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 20-Apr-2023,  after starting mRNA-1273 (Spikevax), the patient experienced EXPIRED PRODUCT ADMINISTERED (HCP stated a patient received 1 dose of Moderna COVID-19 Vaccine monovalent on 20 APR 2023 for the 2nd dose of the primary series, but the vaccine expired on 30 MAR 2023.). On an unknown date, the patient experienced WRONG PRODUCT ADMINISTERED (The vaccine was administered after the indications changed and the monovalent is no longer authorized.) and NO ADVERSE EVENT (No Adverse Event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (HCP stated a patient received 1 dose of Moderna COVID-19 Vaccine monovalent on 20 APR 2023 for the 2nd dose of the primary series, but the vaccine expired on 30 MAR 2023.), WRONG PRODUCT ADMINISTERED (The vaccine was administered after the indications changed and the monovalent is no longer authorized.) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse Event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (HCP stated a patient received 1 dose of Moderna COVID-19 Vaccine monovalent on 20 APR 2023 for the 2nd dose of the primary series, but the vaccine expired on 30 MAR 2023.) and WRONG PRODUCT ADMINISTERED (The vaccine was administered after the indications changed and the monovalent is no longer authorized.).    No concomitant medications were reported. Patient received 1 dose of Moderna COVID-19 Vaccine monovalent for the second dose. It was unknown if the first dose of the primary series was Moderna but assumed that it was Moderna. No treatment details were reported.
Age: 73.0
Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: no adverse event; 1 dose of Moderna bivalent was given BUD; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (1 dose of Moderna bivalent was given BUD) and NO ADVERSE EVENT (no adverse event) in a 73-year-old patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 066H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 19-Apr-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 19-Apr-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (1 dose of Moderna bivalent was given BUD). On an unknown date, the patient experienced NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (1 dose of Moderna bivalent was given BUD) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (1 dose of Moderna bivalent was given BUD).    No concomitant medication were reported. No treatment information was provided by the reporter.
Sex: U
Vaccine: COVID19-2
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; Received a dosage of 0.2 ml of the bivalent vaccine dark pink cap with yellow border as their primary; This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (Received a dosage of 0.2 ml of the bivalent vaccine dark pink cap with yellow border as their primary) and NO ADVERSE EVENT (No adverse event) in an infant patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 216K22A) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: Rotavirus (Rota tec), PCV 13, ACT Hib and Pediarix. Past adverse reactions to the above products included No adverse event with Rotavirus (Rota tec), PCV 13, ACT Hib and Pediarix. Concurrent medical conditions included Lactose intolerant, Cow's milk protein allergy and Pollen allergy (Seasonal).    On 19-Apr-2023, the patient received second dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .2 milliliter. On 19-Apr-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced WRONG PRODUCT ADMINISTERED (Received a dosage of 0.2 ml of the bivalent vaccine dark pink cap with yellow border as their primary). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Received a dosage of 0.2 ml of the bivalent vaccine dark pink cap with yellow border as their primary) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Received a dosage of 0.2 ml of the bivalent vaccine dark pink cap with yellow border as their primary).    Concomitant medication was not provided.  Treatment information was not provided.  This case contains information for the 1st patient out of 4 infant patients as described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-720525, US-MODERNATX, INC.-MOD-2023-720526, US-MODERNATX, INC.-MOD-2023-720527 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 20-Apr-2023: Live significant follow up appended: Added patient details, vaccination details and event information; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-720526:Infant Patient - 3 US-MODERNATX, INC.-MOD-2023-720527:Infant Patient - 4 US-MODERNATX, INC.-MOD-2023-720525:Infant Patient - 2